Clinical Trials- Lymphoma

 NHL  An Open-Label, Randomized, Phase 2 Study to Assess the Effectiveness of RCHOP With or Without Velcade in Previously Untreated Patients with Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma (Millennium C05013)  II Marlene Watson RN
Nebraska Methodist Hospital
 NHL  A Phase 2 Multicenter, Investigator-Initiated Study of Oral Ruxolitinib Phosphate for the Treatment of Relapsed or Refractory Diffuse Large B-cell and Peripheral T-cell Non Hodgkin Lymphoma  II  Susan Blumel  Nebraska Medical Center, Omaha, NE
  NHL Phase I/II Study of Lenalidomide Maintenance Following BEAM (+/- Rituximab) for Chemo-Resistant or High Risk Non-Hodgkin's Lymphoma  II/II  Mary Mailliard  Nebraska Medical Center, Omaha, NE
 T-Cell Phase I Study of Carfilzomib for the Treatment of T-Cell Lymphoma  I  Susan Kruse  Nebraska Medical Center, Omaha, NE
NHL and Plasmablastic Phase II Study of Dose-Adjusted EPOCH +/- Rituximab in Adults with Untreated Burkitt Lymphoma, C-Myc Positive Diffuse Large B-Cell Lymphoma and Plasmablastic Lymphoma  II  Susan Allen  Nebraska Medical Center, Omaha, NE
 NHL, diffuse large B-cell; Mantel cell; Follicular An Open-Label Phase II Study of BKM120 in Patients with Relapsed and Refractory Diffuse Large B-Cell Lymphoma, Mantel Cell Lymphoma and  Follicular Lymphoma (CBKM120Z23402)  II  Maribeth Hohenstein  Nebraska Medical Center, Omaha, NE
NHL, Follicular A Phase 3 Open-Label, Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) versus Rituximab Plus Chemotherapy followed by Rituximab in Subjects with Previously Untreated Follicular Lymphoma  III Susan Allen  Nebraska Medical Center, Omaha, NE
 NHL Phase II Open-Label Study of Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Indolent B-cell Non-Hodgkin's  Lymphoma (B-NHL) Which Has Relapsed after Rituximab or Rituximab-Containing Therapy (GSK Protocol: OFB114612)  II  Maribeth Hohenstein  Nebraska Medical Center, Omaha, NE
 Mantel Cell A Phase 2, Multicenter, Single-Arm Study to Evaluate the Efficacy and Safety of Single-Agent Bruton's Tyrosine Kinase(BTK) Inhibitor, Ibrutinib, in Subjects with Mantle Cell Lymphoma Who Progress after Bortezomib Therapy  II  Maribeth Hohenstein  Nebraska Medical Center, Omaha, NE
 Lymphoid Malignancies A Phase I Dose Escalation Study of OMP-52M51 in Subjects with Lymphoid Malignancies  I  Susan Allen  Nebraska Medical Center, Omaha, NE

Nebraska Oncology Society
c/o Nebraska Medical Association
Sarah Dunbar
Executive Director
233 South 13th Street Suite 1200
Lincoln, NE 68508 (email)
402-474-4472 (phone)
402-474-2198 (fax)

Powered by Wild Apricot Membership Software